<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35583051</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1615-9314</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of separation science</Title>
          <ISOAbbreviation>J Sep Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of Molnupiravir, Favipiravir, and Ritonavir in pure forms and pharmaceutical formulations.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jssc.202200178</ELocationID>
        <Abstract>
          <AbstractText>Favipiravir, molnupiravir, and ritonavir have been recently approved as the first oral antivirals for treatment of SARS-CoV-2 viral infections. Their combination was reported in several clinical studies, alternatively, to enhance the viral eradication and improve patient's recovery times and rates. Being all orally administered, therefore, developing new sensitive and validated methodologies for their simultaneous determination is a necessitate. In the proposed research, a sensitive, selective and simple high-performance thin layer chromatography method was developed and validated for determination of favipiravir, molnupiravir, and ritonavir. Silica gel 60F254 thin layer chromatography plates were used as stationary phase for this separation using mobile phase composed of methylene chloride: ethyl acetate: methanol: 25% ammonia (6:3:4:1, v/v/v/v). Densitometric detection was performed at wavelength 289nm. Peaks of favipiravir, molnupiravir, and ritonavir were resolved at retention factors 0.22, 0.42 and 0.63, respectively. The proposed method was found linear within the specified ranges of 3.75-100.00 μg/mL for molnupiravir and favipiravir, and 2.75-100.00 μg/mL for ritonavir. Limits of detection were found to be 1.12, 1.21, and 0.89 μg/mL for favipiravir, molnupiravir, and ritonavir, respectively. This is the first method to be reported for the simultaneous determination of the cited three antiviral drugs. The method was assessed on novel greenness metrics. This article is protected by copyright. All rights reserved.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Saraya</LastName>
            <ForeName>Roshdy E</ForeName>
            <Initials>RE</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical analytical chemistry department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deeb</LastName>
            <ForeName>Sami El</ForeName>
            <Initials>SE</Initials>
            <Identifier Source="ORCID">0000-0001-6417-4737</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Medicinal and Pharmaceutical Chemistry, Technische Universitaet Braunschweig, 38106, Braunschweig, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa, 616, Sultanate of Oman.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salman</LastName>
            <ForeName>Baher I</ForeName>
            <Initials>BI</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Assiut branch, Assiut, 71524, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ibrahim</LastName>
            <ForeName>Adel Ehab</ForeName>
            <Initials>AE</Initials>
            <Identifier Source="ORCID">0000-0001-7421-1220</Identifier>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical analytical chemistry department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa, 616, Sultanate of Oman.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Sep Sci</MedlineTA>
        <NlmUniqueID>101088554</NlmUniqueID>
        <ISSNLinking>1615-9306</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">COVID-19 Regimen</Keyword>
        <Keyword MajorTopicYN="N">Favipiravir</Keyword>
        <Keyword MajorTopicYN="N">High-performance thin-layer chromatography</Keyword>
        <Keyword MajorTopicYN="N">Molnupiravir</Keyword>
        <Keyword MajorTopicYN="N">Ritonavir</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>54</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35583051</ArticleId>
        <ArticleId IdType="doi">10.1002/jssc.202200178</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
